BMY-28100 IN SURGICAL SKIN AND SOFT-TISSUE INFECTIONS

• Published in: CHEMOTHERAPY Vol. 37; no. Supplement3; pp. 715 - 723
• Main Authors: YOKOYAMA, ISAO, TSUYUKI, KEN, SAITO, TOSHIAKI, NAKATSU, TAKAYOSHI, ARAI, TAKEYUKI
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1989; 公益社団法人 日本化学療法学会
• Subjects: BMY-28100; 外科的感染症; 皮膚軟部組織感染症; 細菌学的効果; 臨床効果
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.37.Supplement3_715

We conducted a clinical evaluation of BMY-28100, a new non-ester type cephalosporin, in the surgical field. BMY-28100 was administered to 24 patients with various surgical infections, without 2 drop out cases. The clinical effect was excellent in 3, good in 19, fair in none and poor in 2, with an overall efficacy rate of 91.7%. High clinical efficacy was observed in infectious atheroma, paronychia, abscess and mastitis, the efficacy rate for these diseases being 87.5%, 100%, 100% and 100%, respectively. The clinical efficacy rate classified by isolated organism was as follows: 100%(12/12) against Gram-positive cocci, 100%(7/7) against Gram-negative bacilli and 100%(9/9) against anaerobes. The eradication rate was 100%. No side effects due to administration of BMY-28100 were experienced, and no abnormal laboratory findings ocurred in any of the cases.